Envara Health Launches Encala, Supplement to Enhance Fat Absorption in CF Patients
Envara Health has launched Encala (formerly Lym-X-Sorb), a nutritional supplement designed to improve fat and nutrient absorption in people with cystic fibrosis (CF) and pancreatic insufficiency.
Encala is indicated for adults and children older than 1 who have started eating toddler or family table food. According to a company press release, the therapy will be commercially available as 15-serving pouches in November. Single-serving sticks for on-the-go consumption will be available in January.
Digestive issues occur in up to 90% of CF patients and they often are linked to mucus accumulation in the pancreas. The mucus blocks the release of enzymes needed for digestion, causing pancreatic insufficiency. The resulting poor nutrient and fat absorption can cause developmental problems, low weight, and chronic malnutrition. Insufficient caloric absorption also accelerates progression of lung disease in CF patients.
Pancreatic enzyme replacement therapy (PERT) temporarily replaces the missing enzymes. Although it often is prescribed in cases of pancreatic insufficiency, it can improve fat absorption to only a limited degree.
Encala is a plant-based, non-GMO (genetically modified organism), gluten-free, and flavorless powder. It provides various kinds of easily-absorbed fats and offers an alternative to other less absorbable fats typically derived from palm, coconut or vegetable oils found in most nutritional supplements.
Encala’s fats are formulated to be easily absorbed without the need for enzyme replacement or digestion. Encala’s fats also help patients absorb other fat-soluble vitamins — those that combine well with fats — found in their diet.
The supplement’s ability to boost fat absorption was demonstrated recently in a Phase 2 clinical trial. Children with CF and pancreatic insufficiency between the ages of 5 and almost 18 years were randomized to receive either Encala or a placebo.
Participants using Encala who had poor fat absorption — those with a coefficient of fat absorption less than 88%, compared to the 93% minimum considered healthy — experienced significant improvements in fat levels, height, weight, and body mass index measurements.
The trial also showed Encala to be both safe and well-tolerated. No undesirable side effects were reported.
“The field of medical nutrition needs innovative solutions to help improve quality of life for patients with malabsorption,” said Virginia A. Stallings, MD, founder and medical advisor to Envara Health. “Encala is the only therapy that has been clinically proven to add healthy calories and provide additional fat absorption beyond the use of PERT. This will help both children and young adults reach their growth and nutritional goals.”
Jim O’Connell, CEO and co-founder of Envara Health, added: “There is tremendous potential for this new technology to revolutionize clinical nutrition across a broad range of diseases.”
About the Author
